Antipsychotic drugs and catecholamine synapses.
D014150:Antipsychotic Agents / Q000494:pharmacology*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001667:Binding, Competitive; D001921:Brain / Q000201:enzymology / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D011955:Receptors, Drug; D012110:Reserpine / Q000378:metabolism / Q000494:pharmacology; D012559:Schizophrenia / Q000188:drug therapy; D012701:Serotonin / Q000378:metabolism; D013268:Stimulation, Chemical; D013881:Thioridazine / Q000378:metabolism; D014443:Tyrosine / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors
D014150:Antipsychotic Agents; D002395:Catecholamines; D011955:Receptors, Drug; D012701:Serotonin; D014443:Tyrosine; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D014446:Tyrosine 3-Monooxygenase; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine; D004298:Dopamine